Unlock the power of real-world evidence (RWE) in drug development with protocol-based disease registries. These clinically rich sources of real-world data (RWD) are purpose-built for research, offering valuable insights into treatment patterns, effectiveness outcomes, and the natural history of diseases.
In this XTalks webinar, CorEvitas’ Vice President Scientific Affairs, Peter Wahl, and Vice President Biostatistics, Heather Litman, join a panel of industry leaders to explore:
- The types of RWD that can be collected in registries
- How RWD can be used to conduct nested, customized registry-based studies
- How to ensure data are collected consistently across patients, practice settings, geography and time
- How to determine if and what kind of registry you require
- What regulators say about using RWD from registries to inform their decision making
- Whether registry data can be used and linked to other data sources
- How to get from data to actionable insights
